|Jump to:||Authorized Access|||||Attribution|||||Authorized Requests|
- Study Description
Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts have formed the Pancreatic Cancer Cohort Consortium. This study, also known as "PanScan", is funded by the National Cancer Institute (NCI) and involves conducting a genome-wide scan of common genetic variants to identify markers of susceptibility to pancreatic cancer. The study team includes the intramural and extramural research community associated with the NCI cohort consortium and Panc4 consortium of case control studies. PanScan employs a two-stage design, with a nested-case-control study of 2000 incident pancreatic cancer cases and 2000 controls for the initial scan (including 1600 cases and 1600 controls from cohort studies along with 400 cases and 400 controls from the Mayo Clinic Molecular Epidemiology of Pancreatic Cancer Case-Control Study). The subsequent validation study will genotype the top ~100 candidate SNPs in an additional 2100 cases and 2100 controls from the PanC4 Case-Control Consortium. The NCI Core Genotyping Facility conducted the genotyping.
- Study Weblink: Pancreatic Cancer Cohort Consortium
- Study Types: Cohort, Nested Case-Control
Number of study subjects that have individual level data available through Authorized Access: 3832
- Authorized Access
- Publicly Available Data (Public ftp)
Connect to the public download site. The site contains release notes and manifests. If available, the site also contains data dictionaries, variable summaries, documents, and truncated analyses.
- Study Inclusion/Exclusion Criteria
Within the cohorts, PanScan will be a nested case control study. Cases will include all incident primary pancreatic adenocarcinomas (ICD-O-3 code C250-C259 or C25.0-C25.3, C25.7-C25.9). Our case definition will exclude endocrine pancreatic tumors (C25.4, histology type, 8150, 8151, 8153, 8155, 8240) because the etiology of these cancers is thought to be different.
- Molecular Data
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Genome Genotyping Illumina HumanHap550v3.0 561466 51468
- Study History
1. The Pancreatic Cancer Cohort Consortium
Each of the member studies of the Cohort Consortium participating in this GWAS is a prospective study of a defined population with blood or buccal cells collected prior to the occurrence of pancreatic cancer. Study characteristics vary but the common and standard prospective cohort design allows for rigorous pooled analysis.
2. Mayo Clinic Molecular Epidemiology of Pancreatic Cancer Case-Control Study
The Mayo Clinic study was initiated in 2000 and uses an "ultra-rapid" case ascertainment system with > 95% of all patients from Minnesota, Iowa, and Wisconsin suspected with pancreatic cancer at the Mayo Clinic being approached. Among the patients diagnosed with pancreatic cancer, 72% provided proper consent and a blood sample for DNA. Clinic controls were frequency matched to cases on age, race, gender, and residence. Patients coming in for a general medical exam in Community, General or Area Internal Medicine were recruited for participation as controls. Inclusion criteria included being resident in Minnesota, Iowa, or Wisconsin, mentally competent, and at least 18 years old. Exclusion criteria included not being able to understand English or to complete an informed consent form, and having a prior history of cancer (except non-melanoma skin cancer), intraductal papillary mucinous tumors (IPMT), intraductal papillary mucinous neoplasia, islet cell tumor, or hereditary, chronic, or acute pancreatitis. Subjects who consented to be in the study provided venous blood samples which were aliquoted for serum, plasma, lymphocyte DNA, and viable frozen cells.
- Selected publications
- Diseases/Traits Related to Study (MESH terms)
- Primary Phenotype: Pancreatic Neoplasms
- Study Attribution